Conference Intelligence Dossier: ECCO 15 - ESMO 34 Congress, 2009
Every year, the numbers grow exponentially: 10.9 million new cancer diagnoses worldwide, 6.7 million cancer deaths annually.
But as the number of cases expand, so, too, does the number of five-year survivors—and the amount of groundbreaking oncology research, new drugs developed and biotechnology innovations. From the impact of Avastin in combination with chemotherapy to the hopeful results for HER2-positive gastric patients treated with Herceptin, the world of oncology is expanding its knowledge base at a rapid pace. These and other critical international developments were recently discussed at the ECCO 15 – ESMO 34 Congress, held September 20 to 24.
FirstWord’s Conference Intelligence Dossier: ECCO 15 - ESMO 34 Congress, 2009 takes you behind the scenes at the conference, where 15,000 cancer researchers, key opinion leaders, physicians and pharmaceutical companies gathered in Berlin, Germany to hear 2,000 presentations covering the entire spectrum of cancer, from research to prevention and through key fields, including breast colorectal, breast, lung, head-and-neck and gastrointestinal cancer.
Key insights from the conference
FirstWord’s wide-ranging report succinctly summarizes the most important news, results and outcomes from one of Europe’s largest and most important oncology congresses into easy-to-access, concise segments. The conference dossier provides accurate reviews of major clinical trial results, conveniently ordered according to specific fields of oncology. And unlike any other report, FirstWord’s Conference Intelligence Dossier: ECCO 15 - ESMO 34 Congress, 2009 offers a unique analysis of the use of social media at scientific congresses, the lessons and successes – and how the pharmaceutical industry can best employ it to capture issues and the attention of health care professionals.
The report’s overview of the conference offers:
But as the number of cases expand, so, too, does the number of five-year survivors—and the amount of groundbreaking oncology research, new drugs developed and biotechnology innovations. From the impact of Avastin in combination with chemotherapy to the hopeful results for HER2-positive gastric patients treated with Herceptin, the world of oncology is expanding its knowledge base at a rapid pace. These and other critical international developments were recently discussed at the ECCO 15 – ESMO 34 Congress, held September 20 to 24.
FirstWord’s Conference Intelligence Dossier: ECCO 15 - ESMO 34 Congress, 2009 takes you behind the scenes at the conference, where 15,000 cancer researchers, key opinion leaders, physicians and pharmaceutical companies gathered in Berlin, Germany to hear 2,000 presentations covering the entire spectrum of cancer, from research to prevention and through key fields, including breast colorectal, breast, lung, head-and-neck and gastrointestinal cancer.
Key insights from the conference
FirstWord’s wide-ranging report succinctly summarizes the most important news, results and outcomes from one of Europe’s largest and most important oncology congresses into easy-to-access, concise segments. The conference dossier provides accurate reviews of major clinical trial results, conveniently ordered according to specific fields of oncology. And unlike any other report, FirstWord’s Conference Intelligence Dossier: ECCO 15 - ESMO 34 Congress, 2009 offers a unique analysis of the use of social media at scientific congresses, the lessons and successes – and how the pharmaceutical industry can best employ it to capture issues and the attention of health care professionals.
The report’s overview of the conference offers:
- The key final and interim results for a number of important clinical trials grouped by field, including:
- Roche’s Xeloxa study
- Phase III results for Amgen Inc’s Vectibix plus chemotherapy treatment study
- Initial outcomes for the BOXER/Avastin trial
- An analysis of the ToGA/Herceptin outcomes for HER2-positive gastric patients
- Analysis of the ZODIAC/Vandetanib trial
- Results of the TEAM study comparing Tamoxifen to Exemestane
- Conclusions from the Sanofi-aventis TAX324 study
- Brief outlines of all relevant drug posters
- Unique quantitative and qualitative analysis of the conference’s use of social media such as Twitter, shared content, professional networking and Facebook, as well an analysis of how the pharmaceutical industry can harness the new technology to access health care professionals, improve quality of engagement and build reputations in communities of interest
- Additional information including key presenter biographies
EXECUTIVE SUMMARY
SOCIAL MEDIA ACTIVITY AT THE CONGRESS
CLINICAL TRIAL UPDATES
Gastrointestinal (GI) Malignancies
Non-colorectal GI Cancer
The UK ABC-02 trial
Sunitinib (SU) versus placebo for treatment of progressive, well-differentiated pancreatic islet cell tumours
Final results of Phase III study of axitinib (AG-013736; A) plus gemcitabine in pancreatic cancer
ToGA trial
Posters on non Colorectal
Colorectal Cancer
AGITG MAX trial –Final results
The FIRIS study
'181' trial- panitumumab with FOLFIRI versus FOLFIRI
XELOXA STUDY
PRIME trial-(Panitumumab Randomised trial In combination with chemotherapy for Metastatic colorectal cancer to determine Efficacy)
COIN Study
Posters on Colorectal cancer
Lung Cancer
ZODIAC trial
WJTOG 3405
Gefitinib response in patients with EGFR mutation
ZEST STUDY
Final NATCH data
SATURN study
NEJ002 study: A randomised Phase III study comparing 4 gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first-line treatment of non-small-cell lung cancer (NSCLC) with sensitive EGFR mutations
Posters on lung cancer
Breast Cancer
Breast Cancer - Early Disease
IES study: Intergroup Exemestane Study
ZORO study: Zoladex Rescue of Ovarian Function
TEAM study: Tamoxifen Exemestane Adjuvant Multinational study
ABCSG-24 study- Austrian Breast Cancer and Colorectal Cancer Study Group
Breast Cancer - Advanced Disease
MONICa: Mono efficacy of Capecitabine
CIRG/TORI 010: first analysis of a randomised Phase II trial of motesanib plus weekly paclitaxel (P) as first line therapy in HER2-negative metastatic breast cancer
A 3-arm randomised Phase II study of oral vinorelbine (NVBo) plus capecitabine (X) versus NVBo and X in sequential versus docetaxel (D) plus X in patients with metastatic breast cancer (MBC) previously treated with anthracyclines
Breast Cancer - Bisphosphonates
Denosumab versus zoledronic acid
Posters on breast cancer
Prostate cancer
Overall survival in men with and without prevalent vertebral fracture receiving androgen deprivation therapy for non-metastatic prostate cancer
Head and Neck
Results of TAX324
Ovarian Cancer
MORAb-003
Posters on ovarian cancer
Renal Cancer
SOCIAL MEDIA AT ECCO 15 - ESMO 34
Quantitative and qualitative activity analyses
Twitter: status updating
Facebook: social networking
Shared content: video, image, and document services
Professional networking
Social media spotlights: activity analysis at ECCO 15 - ESMO 34 by constituency
Key opinion leaders
Pharmaceutical industry
Professional societies
Trending topics within social media at ECCO 15 - ESMO 34
Issues: debate, interaction, conversation and comment
Events: planned, spontaneous, formal and casual
Beyond the conference centre
Blog coverage of ECCO 15 - ESMO 34
Overview
Levels of social media activity at ECCO 15 - ESMO 34 and beyond
Counterpoints: social media representations of ECCO 15 - ESMO 34
BIOGRAPHIES OF KEY PRESENTERS
APPENDIX
INDEX
SOURCES
SOCIAL MEDIA ACTIVITY AT THE CONGRESS
CLINICAL TRIAL UPDATES
Gastrointestinal (GI) Malignancies
Non-colorectal GI Cancer
The UK ABC-02 trial
Sunitinib (SU) versus placebo for treatment of progressive, well-differentiated pancreatic islet cell tumours
Final results of Phase III study of axitinib (AG-013736; A) plus gemcitabine in pancreatic cancer
ToGA trial
Posters on non Colorectal
Colorectal Cancer
AGITG MAX trial –Final results
The FIRIS study
'181' trial- panitumumab with FOLFIRI versus FOLFIRI
XELOXA STUDY
PRIME trial-(Panitumumab Randomised trial In combination with chemotherapy for Metastatic colorectal cancer to determine Efficacy)
COIN Study
Posters on Colorectal cancer
Lung Cancer
ZODIAC trial
WJTOG 3405
Gefitinib response in patients with EGFR mutation
ZEST STUDY
Final NATCH data
SATURN study
NEJ002 study: A randomised Phase III study comparing 4 gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first-line treatment of non-small-cell lung cancer (NSCLC) with sensitive EGFR mutations
Posters on lung cancer
Breast Cancer
Breast Cancer - Early Disease
IES study: Intergroup Exemestane Study
ZORO study: Zoladex Rescue of Ovarian Function
TEAM study: Tamoxifen Exemestane Adjuvant Multinational study
ABCSG-24 study- Austrian Breast Cancer and Colorectal Cancer Study Group
Breast Cancer - Advanced Disease
MONICa: Mono efficacy of Capecitabine
CIRG/TORI 010: first analysis of a randomised Phase II trial of motesanib plus weekly paclitaxel (P) as first line therapy in HER2-negative metastatic breast cancer
A 3-arm randomised Phase II study of oral vinorelbine (NVBo) plus capecitabine (X) versus NVBo and X in sequential versus docetaxel (D) plus X in patients with metastatic breast cancer (MBC) previously treated with anthracyclines
Breast Cancer - Bisphosphonates
Denosumab versus zoledronic acid
Posters on breast cancer
Prostate cancer
Overall survival in men with and without prevalent vertebral fracture receiving androgen deprivation therapy for non-metastatic prostate cancer
Head and Neck
Results of TAX324
Ovarian Cancer
MORAb-003
Posters on ovarian cancer
Renal Cancer
SOCIAL MEDIA AT ECCO 15 - ESMO 34
Quantitative and qualitative activity analyses
Twitter: status updating
Facebook: social networking
Shared content: video, image, and document services
Professional networking
Social media spotlights: activity analysis at ECCO 15 - ESMO 34 by constituency
Key opinion leaders
Pharmaceutical industry
Professional societies
Trending topics within social media at ECCO 15 - ESMO 34
Issues: debate, interaction, conversation and comment
Events: planned, spontaneous, formal and casual
Beyond the conference centre
Blog coverage of ECCO 15 - ESMO 34
Overview
Levels of social media activity at ECCO 15 - ESMO 34 and beyond
Counterpoints: social media representations of ECCO 15 - ESMO 34
BIOGRAPHIES OF KEY PRESENTERS
APPENDIX
INDEX
SOURCES